Relative vs Absolute Risk: How to Read the Numbers Honestly

A plain-language guide to the two ways risk gets reported, and why the difference changes how you should weigh a treatment.

Relative risk reduction tells you how much a treatment cuts a bad outcome as a percentage of the original risk. Absolute risk reduction tells you how many people out of a hundred actually avoid that outcome. The same study can honestly report "50 percent lower risk" and "1 fewer person in 100," because relative vs absolute risk measure different things. Knowing which one you are reading is the whole game.

I bring this up with patients more often than almost any other topic, because the numbers in a headline rarely lie, but they are easy to misread. A drug can sound dramatic and still help only a small slice of people, and a modest-sounding result can be genuinely meaningful for the right person. The math is not hard. It is just usually skipped.

What does relative risk reduction actually mean?

Relative risk reduction compares two groups and asks how much smaller one group's risk is compared to the other. If 2 out of 100 people have an event without treatment, and 1 out of 100 have it with treatment, the treatment cut the risk in half. That is a relative risk reduction of 50 percent.

It is a ratio. It throws away the starting point on purpose. A 50 percent reduction sounds identical whether you started at 2 in 100 or 200 in 100,000, even though those are very different real-world situations. The percentage is true in both cases. It just does not tell you how common the problem was to begin with.

What does absolute risk reduction mean?

Absolute risk reduction is the plain subtraction. You take the risk in the untreated group and subtract the risk in the treated group. In the example above, 2 percent minus 1 percent equals 1 percent. So the absolute risk reduction is 1 percentage point.

That single number answers the question most people actually care about: out of everyone like me who takes this, how many extra people avoid the bad outcome? Absolute numbers stay grounded in real people. They do not inflate when the baseline risk is tiny, and they do not shrink when the baseline is large. This is why, when I read a trial, I look for the absolute figures first and treat the relative ones as context.

Why can a big relative number be small in absolute terms?

Here is the part that trips up smart people. The relative number depends entirely on how common the outcome was to start. When a condition is rare, even a large relative reduction moves very few actual lives.

Picture an outcome that happens to 1 person in 1,000. A treatment that "halves your risk" sounds powerful. But cutting 1 in 1,000 down to 0.5 in 1,000 means the absolute benefit is half a person per thousand treated. The 50 percent is honest. It is also nearly weightless in day-to-day terms. Now flip it. If an outcome happens to 200 people in 1,000, that same 50 percent reduction prevents it in 100 people. Identical relative number, wildly different human impact. The relative figure cannot tell you which situation you are in. Only the absolute figure can.

What is number needed to treat, in plain words?

Number needed to treat, or NNT, is the absolute risk reduction turned into a count you can picture. It answers: how many people need to take this for one person to benefit who would not have otherwise?

The math is simple. You divide 1 by the absolute risk reduction expressed as a decimal. If the absolute reduction is 1 percent, that is 0.01, and 1 divided by 0.01 is 100. So 100 people take the treatment for 1 to get the specific benefit being measured. A small NNT, like 10, means the treatment helps a lot of the people who take it. A large NNT, like 500, means most people who take it get no benefit on that particular outcome, though a few are helped a great deal.

• Absolute risk reduction of 5 percent means an NNT of 20.
• Absolute risk reduction of 2 percent means an NNT of 50.
• Absolute risk reduction of 0.5 percent means an NNT of 200.

NNT is not a verdict. A high number can still be worth it when the outcome it prevents is severe, such as a heart attack or a stroke. But it forces an honest conversation about who is likely to gain and who is along for the ride.

How do headlines lean on relative framing?

Relative numbers are bigger, so they make better headlines. "Cuts risk by 40 percent" reads as more newsworthy than "1 in 80 people benefit," even when those two phrases describe the same study. There is nothing dishonest about reporting a relative reduction. The trouble starts when the relative figure appears alone, with no baseline and no absolute counterpart, so the reader has no way to judge scale.

I see this pattern in press releases, supplement ads, and the occasional weight-loss promotion. The relative number is real. The missing context is what does the work of making it sound larger than the lived benefit. When you only get the percentage and never the count, that is your signal to slow down and ask for the other half.

How do I ask "out of how many people?"

This is the one habit I want every patient to keep. Whenever you hear a risk claim, ask out of how many people that benefit applies. It is a polite, powerful question, and any good source can answer it.

• If you hear a percent reduction, ask what the starting risk was.
• If you hear "lowers risk," ask by how many people out of 100, not just by what percentage.
• If you hear an impressive result, ask for the number needed to treat.
• If no one can tell you the baseline, treat the claim as incomplete rather than wrong.

You do not need a statistics background to do this. You need one question, asked consistently. It converts a vague impression into something you can actually weigh.

Why does this matter for weight and metabolic decisions?

Weight and metabolic medicine is full of numbers, and they deserve the same honest reading. When I discuss the GLP-1 medications we use, I try to share figures the way I would want them shared with me. In the STEP-1 trial, semaglutide produced an average of about 14.9 percent of body weight lost. In SURMOUNT-1, tirzepatide produced an average of about 20.9 percent. Those are averages, which means real people landed above and below them. The SELECT trial showed a cardiovascular benefit for semaglutide in adults who already had established cardiovascular disease along with overweight or obesity, and that benefit is best understood in absolute terms for your own situation, not as a headline percentage.

A note I am required to make, and that I make gladly because it is true: compounded semaglutide and compounded tirzepatide are not FDA-approved and are not identical to the brand versions. Results vary by individual. Ozempic and Wegovy are products of Novo Nordisk, and Mounjaro and Zepbound are products of Eli Lilly; we are not affiliated with either company. None of that changes the lesson here. Whatever you are considering, ask for the absolute numbers and the baseline before you decide.

At New Hope Weight Loss and Wellness, our visits are cash-pay, telehealth, bilingual, and HIPAA-private, with no insurance needed. A consult is $119. Compounded semaglutide runs $166 a month, about $5.50 a day, with a 90-day Reset at $499. Compounded tirzepatide runs $233 a month, about $7.70 a day, with a 90-day Reset at $699. If you want to test the waters first, the $199 Skeptics Trial covers one month. When we sit down together, I will walk through the figures with you the same way I walked through them here: honestly, both ways, out of how many people.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.